MUSK and Cognitive impairment: Although the pathogenetic mechanisms underlying cognitive impairment during MG are still unclear, disease severity, MuSK antibody positivity, and arm and leg hyposthenia might be factors associated with an increased risk of MCI in patients with MG, while pyridostigmine therapy seems to be able to reduce this risk.